Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 10, 2011. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares under authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share repurchase activity and capital structure updates.
- Shares Purchased: 825,000 ordinary shares of 25 pence each.
- Purchase Date: November 10, 2011.
- Price Range: Highest price paid was 1,386.5 pence per share; lowest price paid was 1,355 pence per share.
- Treasury Holdings (Settled): 516,727,927 shares (9.27% of total issued share capital).
- Treasury Holdings (Including Unsettled): 519,202,927 shares (10.27% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,055,883,555 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 825,000 shares. Consequently, the percentage of shares held in Treasury increased to 9.27% of total issued share capital. The filing notes that the total voting rights denominator for shareholder notification purposes is now 5,055,883,555 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (516,727,927 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (5,055,883,555) for compliance with disclosure thresholds.
- Review the remaining authority for share buybacks under the mandate granted on May 5, 2011.
- Note that this filing does not contain operational or financial performance data for the period.